These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 9115587)

  • 1. Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses.
    Tada M; Iggo RD; Waridel F; Nozaki M; Matsumoto R; Sawamura Y; Shinohe Y; Ikeda J; Abe H
    Mol Carcinog; 1997 Mar; 18(3):171-6. PubMed ID: 9115587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies.
    Watanabe K; Sato K; Biernat W; Tachibana O; von Ammon K; Ogata N; Yonekawa Y; Kleihues P; Ohgaki H
    Clin Cancer Res; 1997 Apr; 3(4):523-30. PubMed ID: 9815715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression.
    Fults D; Brockmeyer D; Tullous MW; Pedone CA; Cawthon RM
    Cancer Res; 1992 Feb; 52(3):674-9. PubMed ID: 1346255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas.
    Lang FF; Miller DC; Pisharody S; Koslow M; Newcomb EW
    Oncogene; 1994 Mar; 9(3):949-54. PubMed ID: 8108140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 mutations in malignant astrocytomas.
    Biernat W; Debiec-Rychter M; Kordek R; Liberski PP
    Pol J Pathol; 1997; 48(4):221-4. PubMed ID: 9529927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects.
    Reilly KM; Loisel DA; Bronson RT; McLaughlin ME; Jacks T
    Nat Genet; 2000 Sep; 26(1):109-13. PubMed ID: 10973261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of a novel point mutation in the p53 gene in grade II astrocytomas by PCR-SSCP analysis with additional Klenow treatment.
    Chawengchao B; Petmitr S; Ponglikitmongkol M; Chanyavanich V; Sangruji T; Theerapuncharoen V; Hayashi K; Thangnipon W
    Anticancer Res; 2001; 21(4A):2739-43. PubMed ID: 11724349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular pathogenesis of pediatric astrocytic tumors.
    Nakamura M; Shimada K; Ishida E; Higuchi T; Nakase H; Sakaki T; Konishi N
    Neuro Oncol; 2007 Apr; 9(2):113-23. PubMed ID: 17327574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular genetic analysis of p53 intratumoral heterogeneity in human astrocytic brain tumors.
    Ren ZP; Olofsson T; Qu M; Hesselager G; Soussi T; Kalimo H; Smits A; Nistér M
    J Neuropathol Exp Neurol; 2007 Oct; 66(10):944-54. PubMed ID: 17917588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme.
    Marutani M; Tonoki H; Tada M; Takahashi M; Kashiwazaki H; Hida Y; Hamada J; Asaka M; Moriuchi T
    Cancer Res; 1999 Oct; 59(19):4765-9. PubMed ID: 10519380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mutations of p53 gene in 41 cases of human brain gliomas].
    Cui W; Kong X; Cao HL; Wang X; Gao JF; Wu RL; Wang XC
    Ai Zheng; 2008 Jan; 27(1):8-11. PubMed ID: 18184456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of p53 mutations on prognosis of patients with glioblastoma.
    Shiraishi S; Tada K; Nakamura H; Makino K; Kochi M; Saya H; Kuratsu J; Ushio Y
    Cancer; 2002 Jul; 95(2):249-57. PubMed ID: 12124823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethnicity delineates different genetic pathways in malignant glioma.
    Chen P; Aldape K; Wiencke JK; Kelsey KT; Miike R; Davis RL; Liu J; Kesler-Diaz A; Takahashi M; Wrensch M
    Cancer Res; 2001 May; 61(10):3949-54. PubMed ID: 11358811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the p53 protein in a spectrum of astrocytic tumours.
    Ellison DW; Gatter KC; Steart PV; Lane DP; Weller RO
    J Pathol; 1992 Dec; 168(4):383-6. PubMed ID: 1336544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of p53 autoantibodies in sera from glioma patients.
    Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
    Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the IDH1 codon 132 mutation in brain tumors.
    Balss J; Meyer J; Mueller W; Korshunov A; Hartmann C; von Deimling A
    Acta Neuropathol; 2008 Dec; 116(6):597-602. PubMed ID: 18985363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal expansion of p53 mutant cells is associated with brain tumour progression.
    Sidransky D; Mikkelsen T; Schwechheimer K; Rosenblum ML; Cavanee W; Vogelstein B
    Nature; 1992 Feb; 355(6363):846-7. PubMed ID: 1311419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromosome 10 and 17 deletions and p53 gene mutations in Thai patients with astrocytomas.
    Put-Ti-Noi S; Petmitr S; Chanyavanich V; Sangruji T; Theerapuncharoen V; Hayashi K; Thangnipon W
    Oncol Rep; 2004 Jan; 11(1):207-11. PubMed ID: 14654927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression as exemplified by human astrocytic tumors.
    Collins VP
    Semin Cancer Biol; 1999 Aug; 9(4):267-76. PubMed ID: 10448114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort.
    Pollack IF; Finkelstein SD; Burnham J; Holmes EJ; Hamilton RL; Yates AJ; Finlay JL; Sposto R;
    Cancer Res; 2001 Oct; 61(20):7404-7. PubMed ID: 11606370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.